| Autor: |
Moroni R; Department of Gynecology and Obstetrics, Ribeirão Preto School of Medicine, University of São Paulo, São Paulo, Brazil., Vieira C; Department of Gynecology and Obstetrics, Ribeirão Preto School of Medicine, University of São Paulo, São Paulo, Brazil., Ferriani R; Department of Gynecology and Obstetrics, Ribeirão Preto School of Medicine, University of São Paulo, São Paulo, Brazil., Candido-Dos-Reis F; Department of Gynecology and Obstetrics, Ribeirão Preto School of Medicine, University of São Paulo, São Paulo, Brazil., Brito L; Department of Gynecology and Obstetrics, Ribeirão Preto School of Medicine, University of São Paulo, São Paulo, Brazil. |
| Jazyk: |
angličtina |
| Zdroj: |
Annals of medical and health sciences research [Ann Med Health Sci Res] 2014 Sep; Vol. 4 (Suppl 3), pp. S185-92. |
| DOI: |
10.4103/2141-9248.141955 |
| Abstrakt: |
Uterine fibroids (UF) are common, benign gynecologic tumors, affecting one in three to four women, with estimates of up to 80%, depending on the population studied. Their etiology is not well established, but it is under the influence of several risk factors, such as early menarche, nulliparity and family history. More than 50% of affected women are asymptomatic, but the lesions may be related to bothersome symptoms, such as abnormal uterine bleeding, pelvic pain and bloating or urinary symptoms. The treatment of UF is classically surgical; however, various medical options are available, providing symptom control while minimizing risks and complications. A large number of clinical trials have evaluated commonly used medical treatments and potentially effective new ones. Through a comprehensive literature search using PubMed, EMBASE, CENTRAL, Scopus and Google Scholar databases, through which we included 41 studies out of 7658 results, we thoroughly explored the different pharmacological options available for management of UF, their indications, advantages and disadvantages. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
